Enthera
Pharmaceuticals

A small team in Milan, watching a receptor most of biology ignored

In a building on Via Borgogna in central Milan, a team of roughly eleven people is running clinical trials on two continents. They are not trying to make a chronic disease more bearable. They are trying to make the body fix itself. Enthera Pharmaceuticals has a lead antibody in human testing, papers in Nature Communications and the Journal of Clinical Investigation, and a CEO who joined the board before she ran the place. For a company this size, that is a strange amount of weight to be carrying.

The bet is unusual. Most autoimmune drugs are firefighters - they suppress the immune system so it stops attacking. Useful, but the organ keeps degrading underneath. Enthera went looking for the match instead of the smoke, and it thinks it found one: a single receptor named TMEM219.

Two diseases. Same dying cells. Nobody had connected them.

Type 1 diabetes and inflammatory bowel disease do not look related. One destroys insulin-producing cells in the pancreas. The other inflames and erodes the lining of the gut. Different organs, different symptoms, different specialists. The kind of pair you would never put on the same slide.

Except they share a quiet mechanism. When levels of a protein called IGFBP3 rise, it binds to the TMEM219 receptor and tells cells to die - colonic stem cells in the gut, beta cells in the pancreas. The lining stops regenerating. The insulin factory shuts down. The standard playbook treats the consequences. Enthera went after the signal.

Above: the entire thesis of a biotech company, compressed into a receptor name you will forget by lunch and they will spend a decade on.

A spin-off, a record check, and a name nobody could pronounce

Enthera was formed in 2016 on research by Prof. Paolo Fiorina and Dr. Francesca D'Addio. It became the first spin-off of BiovelocITA, Italy's first biotech accelerator, founded by Sofinnova Partners with Silvano Spinelli and Gabriella Camboni. The accelerator wrote the first seed check. Then the science had to earn the rest.

It did. In July 2020, Enthera raised €28 million in Series A financing, co-led by Sofinnova Partners and AbbVie, with the JDRF T1D Fund and several Italian investors joining in. At the time it was reported as the largest international VC-backed Series A for biotech in Italy. When a pharma giant like AbbVie writes a check into your pathway, the smoke-versus-match argument gets a little more interesting.

Four numbers a venture investor reads in eight seconds, and a founder spends eight years earning.

Ebrasodebart: the antibody that tells cells to stop dying

The lead candidate has a generic name almost designed to be misremembered - ebrasodebart, internally Ent001. It is a first-in-class monoclonal antibody that blocks the IGFBP3/TMEM219 signal. Block the signal, and the apoptosis order never arrives. The stem cells live. In theory, the gut lining rebuilds and the pancreatic stem-cell compartment re-establishes itself.

That is the whole idea: restoration, not suppression. Whether biology cooperates is exactly what the clinic is now testing.

Receipts, not just a hypothesis

Ideas are cheap in biotech. Enthera has tried to make its expensive. The pancreatic side of the story was published with Boston Children's Hospital of Harvard Medical School and the University of Milan in Nature Communications. The gut side landed in the Journal of Clinical Investigation in May 2025, showing TMEM219 driving intestinal stem-cell death and blocking mucosal healing. And the company completed patient enrollment in its Phase 1b proof-of-concept trial in ulcerative colitis - the moment a thesis stops being a slide and starts being data.

Built to be unnecessary

Most chronic-disease companies sell management - a drug you take forever. Enthera's mission points the other way: a disease-modifying treatment that restores what the disease destroyed. If it works, a patient needs it less over time, not more. That is a commercially awkward ambition and a deeply human one, and Enthera has decided to chase the second.

The leadership reflects that translational bet. CEO Lisa M. Olson, Ph.D., spent over two decades in biopharma - including at AbbVie, which later invested - and chaired Enthera's Scientific Advisory Board before taking the top job. Scientific co-founder Paolo Fiorina serves as Chief Scientific Officer, keeping the company close to the academic roots that produced the pathway.

Back on Via Borgogna

Return to that building in Milan. Eleven people, two diseases, one receptor, several years of work either about to pay off or about to teach a hard lesson. That is the honest state of any clinical-stage biotech: the science is published, the trials are running, and biology has not yet given its final answer.

But the room has already changed something. A decade ago, type 1 diabetes and ulcerative colitis were treated as unrelated problems by unrelated fields. Enthera drew a line between them through TMEM219 and put a drug on that line. If ebrasodebart does in patients what it does in the lab, the question stops being how to suppress these diseases and becomes whether you can reverse them. The match, it turns out, is more interesting than the smoke.